REVIEW PAPER
Premenstrual syndrome
1
Samodzielna Pracownia Medycyny Katastrof, Wydział Pielęgniarstwa i Nauk o Zdrowiu, Uniwersytet Medyczny w Lublinie
Med Og Nauk Zdr. 2011;17(3):145-147
KEYWORDS
ABSTRACT
Premenstrual syndrome – PMS is a group of troublesome symptoms of a physical, behavioural and psychological nature, regularly occurring in women during the luteal phase of the menstrual cycle and disappearing when menstruation starts. PMS occurs during the period of puberty and accompanies a woman until menopause. The symptoms are most experienced at the age 25-35 years. The article presents the etiology and clinical aspects of PMS, as well as current principles of therapy. Intensification and type of physical symptoms experienced may vary considerably among women. The physical symptoms of PMS are a significantly disturbed personal, social and occupational life. However, with the symptoms of a moderate in- tensity, these women are capable of functioning and responding to the situational stimuli. Nevertheless, there is a group of women in whom the symptoms are so strongly manifested that they make an adequate functioning in a family, society and work impossible. A severe form of the syndrome, with intensified symptoms, especially psychological, has been named premenstrual dysphoric disorder – PMDD. From 2-6% of women at reproductive age suffer from PMDD.
REFERENCES (31)
1.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV. 4-th ed. American Psychiatric Association, Washington 1994.
2.
Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: defi nition and diagnosis. Psychoneuroendocrinology 2003;2:25- 37.
3.
Yonkers KA, O’Brien PM, Eriksson E. Premenstrual Syndrome. Lancet 2008; 371:1200-1210.
4.
Denster PA, Adera T, South-Paul J. Biological, social behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999;8:122- 128.
5.
Campbell EM, Peterkin A, O’Grady K, et al. Premenstrual symptoms in general practice patients. J Reprod Med 1997;42:637-646.
6.
Johnson SR. Th e epidemiology and social impact of premenstrual syndrome. Clin Obstet Gynecol 1987;30:367-376.
7.
Rubinow D, Schmidt P. Th e neuroendocrinology of menstrual cycle mood disorders. Ann N Y Acad Sci 1995;771:648-659.
8.
Halbreich U. Th e etiology, biology and evolving pathology premenstrual syndromes. Psychoneuroendocrinology 2003;28:55-99.
9.
Rapkin AJ, Edelmuth E, Chang LC, et al. Whole blood serotonin in the premenstrual syndrome. Obstet Gynecol 1987;70:533-537.
10.
Brown J, O’Brien PM, Marjoribanks J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cohrane Database Syst Rev 2009;2:CD001396.
11.
Landen M, Eriksson O, Sundnblad C, et al. Compounds with affi nity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspiron, nefazodone and placebo. Psychopharmacology 2001;155:292-298.
12.
Steinberg S, Annable L, Young S, et al. A placebo-controlled clinic trial L-tryptophan in premenstrual dysphoria. Biol Psychiatry 1999;45:313- 320.
13.
Dimmock PW, Wyatt KM, Jones PW, et al. Effi cacy of selective serotonin- reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000;356:1131-1136.
14.
Steiner M, Romano SJ, Babcock S, et al. Th e effi cacy of fl uoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG 2001;108:462-468.
15.
Halbreich U, Petty F, Yonkers K, et al. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996;156:718-720.
16.
Bloch M, Schmidt PJ, Danaceau M,et al. Eff ects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000;157:924-930.
17.
Mackenzie TB, Wilcox K, Baron H. Lifetime prevalence of psychiatric disorders in women with premenstrual diffi culties. J Aff ect Disord 1986;10:15-19.
18.
American College of Obstetricians and Gynecologist: Premenstrual Syndrome. ACOG Practice Bulletin No. 15, Apr. 2000.
19.
Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome. J Psychosom Res 1998;45:307-318.
20.
Usman SB, Indusekhar R, O’Brien PM. Hormonal management of premenstrual syndrome. Best Practice & Research Clin Obstet Gynaecol 2008;22:251-260.
21.
De Souza MC, Walker AF, Robinson PA, et al. A synergistic eff ects of a daily supplement for one month of 200mg magnesium plus Vit B6 for the reliv of anxiety related premenstrual symptoms: a randomized, double blind, crossover study. J Womens Health Gend Based Med 2000;9:131-139.
22.
Freeman EW, Jabara S, Sonheimer SJ, et al. Citalopram in PMS with prior SSRI treatment failure: a preliminary study. J Wom Health Gend Based Med 2002;11:459-464.
23.
Cohen L, Miner C, Brown E, et al. Premenstrual daily fl uoxetine for premenstrual dysphoric disorder: a placebo- controlled clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-444.
24.
Halbreich U. Bergeron R, Yonkers KA, et al. Effi cacy of intermittent luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-1229.
25.
Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and aft er treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-109.
26.
Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-266.
27.
Freeman EW, Kroll R, Rapkin A, et al. PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Wom Health Gend Based Med 2001;10:561- 569.
28.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009;2:CD006586.
29.
Coff ee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-1319.
30.
Pearlstein TB, Bachmann G, Zacur H, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421.
31.
Yonkers KA, Brown C, Pearlstein T. Effi cacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
| eISSN: | 2084-4905 |
| ISSN: | 2083-4543 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
